Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 248

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 248
---
 the treatment 
 effect for each product. Estimated sample size calculations were based on estimated treatment effect difference between active treatment  
 versus control with 80%- 90% power.                                                                                                       |

| ● | For each product, the estimated time required for FDA approval was nine months. In accordance with the                                
 review timelines specified in 21 CFR. 814, management believes this represents a conservative estimate for PMA filings. Similarly, in 
 accordance with the review timelines specified in the Prescription Drug User Fee Act (“PDUFA”), management believes nine months       
 represents an appropriate review time estimate for the soft tissue product BLA filing.                                                |

| ● | The Projections do not include assumptions for competition or new market entrants. |

| ● | General and administrative expenses during product development are primarily based on detailed staffing,                               
 facility and other administrative costs expected to be incurred. Following product launch, general and administrative expense is based 
 on analysis of cost ratios for fully integrated biopharmaceutical companies as a percentage of revenue.                                |

| ● | Selling and marketing expenses are based on an analysis of cost ratios of fully integrated biopharmaceutical 
 companies as a percentage of revenues.                                                                       |

Opinion of Newbridge

FutureTech retained Newbridge to act as its financial advisor in connection with the Business Combination. Newbridge, as part of its investment banking business, is continually engaged in the valuation of businesses and their securities in connection with mergers and acquisitions, negotiated underwritings, secondary distributions of listed and unlisted securities, private placements and valuations for estate, corporate and other purposes. FutureTech selected Newbridge to act as its financial advisor in connection with the Business Combination on the basis of Newbridge’s experience in similar transactions and its reputation in the investment community.

On September 12 th, 2024, at a meeting of the Board held to evaluate the Business Combination, Newbridge delivered to the FutureTech Board an oral opinion, which was confirmed by delivery of a written opinion, dated October September 16 th, 2024, to the effect that, as of the date of the opinion and based on and subject to various assumptions and limitations described in its written opinion, the Merger Consideration to be paid to the stockholders of Longevity Biomedical, Inc. (“LBI”), is fair, from a financial point of view, to FutureTech’s shareholders.

The full text of Newbridge’s written opinion to the FutureTech Board, which describes, among other things, the assumptions made, procedures followed, factors considered and